HPV Associated Disorders Market Size, Share & Trends Analysis Report By Indication (CIN, Cervical Cancer, AIN, Anal Cancer, Genital Warts), By Therapy (Prevention, Treatment), By Distribution Channel- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global HPV Associated Disorders market size was estimated at USD 3.20 billion in 2021 and is expected to surpass around USD 30.4 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.5% during the forecast period 2022 to 2030.

Growth Factors:

The growing prevalence of HPV-related diseases and increasing penetration of treatment options are expected to drive the market. There are more than 100 strains of HPV, out of which 13 are high risk or cancerous. The degree of risk of each HPV strain is determined by the activated gene-E6 or E7. HPV causes a wide array of diseases, including Cervical Intraepithelial Neoplasia (CIN), cervical cancer, Anal Intraepithelial Neoplasia (AIN), anal cancer, vulvar cancer, oropharyngeal cancer, and genital warts.

Proactive government initiatives and increased funding for cancer research are expected to aid in significant growth in this market. For instance, the 2010 Affordable Care act provides the human papillomavirus vaccine, HPV testing, and Pap testing for most of the covered patients. Although the Healthy People 2020 goal in the U.S. sets a target of 80% vaccination coverage against HPV, a 2017 national survey estimated that only 51% of girls have completed all doses.

Lack of awareness about diagnosis & treatment of such diseases and high-cost of treatment are some factors impeding growth. There is a high unmet need for targeted drugs with improved clinical profile at reduced costs and convenient administration schedule. However, growing R&D expenditure on oncologic diseases offers a promising future for the market in the foreseeable future.

Most HPV associated disorders, especially cervical cancer, develop over a period of 15 to 20 years in women with normal immunity, giving them a significant window for prevention or treatment to limit disease progression. However, in women with low immunity or compromised immune system, disease manifestation generally takes only 5 to 10 years. Precancerous changes in women generally start between 20 and30 years of age, although the average age of diagnosis of most HPV-associated disorders in women is 50 years.

Report Scope of the HPV Associated Disorders Market

Report Coverage


Market Size

US$ 30.4 Billion by 2030

Growth Rate

CAGR of 6.5% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

 Indication, therapy, distribution channel and Region,

Companies Mentioned

 Merck & Co., Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd; Pfizer, Inc.; Allergan plc; AstraZeneca plc; Biocon Ltd.; Eli Lilly and Company. Merck & Co.


HPV Associated Disorders Market Trends

The market for human papillomavirus disorder is anticipated to be driven by an increase in the number of individuals infected with the virus, as well as growing familiarity with the disorder and the availability of new medicines for its treatment.

The global market is also anticipated to benefit from government initiatives and expanded financing for cancer research. The increased expenditure on R&D connected with oncologic disorders, on the other hand, presents significant potential growth for the market.

Furthermore, continuous innovation in healthcare increased consumer awareness and investments in medical infrastructure. Emerging and less developed countries are likely to generate several opportunities that will have an influence on market growth during the forecast period.

However, the absence of public awareness and understanding about the accessibility, usage of vaccines, and HPV, along with rising concerns about the side effects of therapies for a longer period and high cost of treatment alternatives are anticipated to act as significant restraining factors.

Indication Insights

Cervical cancer remained the forerunner among all indications, capturing more than 50% share in 2021. The segment growth is driven by strong commercial performances of Avastin and Keytruda. Avastin’s near-term patent expiry and consequent penetration of biosimilars might alter the therapeutic landscape. Nevertheless, cervical cancer is projected to prevail as the leading segment over the forecast period.

CIN is positioned to demonstrate the fastest growth rate over the forecast period. CIN is a precancerous condition, which may progress into cervical cancer in case of untimely or lack of proper diagnosis & treatment. The segment’s high growth rate is fueled by a high disease prevalence due to growing cases of unprotected sex, people having multiple sex partners, and leading an unhealthy lifestyle.

Therapy Insights

The therapeutic focus has lately shifted towards taking preventive measures, thus driving the vaccine market for human papillomavirus. Currently, there are two commercial vaccines against HPV: Cervarix and Gardasil. In addition, an improvised, nonavalent version of Gardasil, Gardasil 9, was approved by the FDA in 2021. This label expansion gave Gardasil (quadrivalent and nonavalent) a distinct clinical advantage over Cervarix (bivalent).

The emergence of biologics and biosimilars has brought about a positive change in treatment regimens by increasing focus on targeted therapies. Targeted therapies are designed for identifying and counteracting specific disease cells. Avastin’s label expansion in 2020 for cervical cancer marked the introduction of biologics and targeted therapies for HPV associated disorders. Avastin had the monopoly of being the only approved biologic for cervical cancer, until Keytruda’s label expansion in 2018. These drugs have paved the way for more targeted therapies with improved safety and efficacy profiles.

Distribution Channel Insights

Hospital pharmacies captured the largest share among distribution channels in 2021. Hospital pharmacies preserve the stock of products related to HPV associated disorders, mainly for cervical & anal cancer, for outpatients and inpatients. The segment will be driven by growing consumer awareness and increased investments in healthcare infrastructure across developing and underdeveloped economies.

Online pharmacies is the fast-growing segment due to its user-friendly interfaces and convenience in terms of access, prices, and delivery. Moreover, they have certain discounts on purchase of a certain amount or offer bundle pricing for cancer products. The segment will be driven by the increasing penetration of e-commerce.

Regional Insights

North America accounted for more than 70% share in 2018, owing to strong commercial sales of biologics in the U.S. Other factors contributing to the market growth include proactive government initiatives, an increase in healthcare expenditure, and local presence of key manufacturers.

Asia Pacific is projected to observe the fastest growth throughout the forecast period. Swift economic development, improvements in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely factors that contribute to regional growth. Emerging economies of China, India, South Korea, and others are expected to observe strong growth in the coming years.

Recent Developments

  • In May 2022, GSK plc agreed to buy Affinivax, Inc., a diagnostic biopharmaceutical firm established in Cambridge, Massachusetts, for $2.1 billion in cash and potentially $1.2 billion in possible growth milestones. Affinivax is leading the way in the creation of a next-generation pneumococcal vaccine
  • In September 2021, Eli Lilly and UNICEF have established a new partnership to help 10 million children and adolescents with severe non-communicable diseases (NCDs) improve their medical outcomes by 2025. Lilly has pledged $14.4 million to UNICEF's existing work in some countries to address NCD risk factors

Some of the prominent players in the HPV Associated Disorders Market include:  Merck & Co., Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd; Pfizer, Inc.; Allergan plc; AstraZeneca plc; Biocon Ltd.; Eli Lilly and Company. Merck & Co.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global HPV Associated Disorders market

  • Indication
    • CIN
    • Cervical Cancer
    • AIN
    • Anal Cancer
    • Genital Warts
    • Others
  • Therapy
    • Prevention
    • Treatment
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

By Geography

North America

  • U.S.
  • Canada


  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Points Covered in HPV Associated Disorders Market Study:

  • Growth of HPV Associated Disorders in 2022
  • Market Estimates and Forecasts (2017-2030)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for HPV Associated Disorders and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  HPV Associated Disorders Consumption Analysis
  •  HPV Associated Disorders Production Analysis
  •  HPV Associated Disorders and Management